NCT03518060View on ClinicalTrials.gov

Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1

CompletedOBSERVATIONAL
Enrollment

209

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

May 14, 2023

Study Completion Date

May 14, 2023

Conditions
HIV Infections
Interventions
DRUG

JULUCA

JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).

Trial Locations (23)

10117

GSK Investigational Site, Berlin

10243

GSK Investigational Site, Berlin

10629

GSK Investigational Site, Berlin

12163

GSK Investigational Site, Berlin

14057

GSK Investigational Site, Berlin

14059

GSK Investigational Site, Berlin

20146

GSK Investigational Site, Hamburg

20246

GSK Investigational Site, Hamburg

44787

GSK Investigational Site, Bochum

45122

GSK Investigational Site, Essen

48143

GSK Investigational Site, Münster

49090

GSK Investigational Site, Osnabrück

50668

GSK Investigational Site, Cologne

50674

GSK Investigational Site, Cologne

52062

GSK Investigational Site, Aachen

72076

GSK Investigational Site, Tübingen

80331

GSK Investigational Site, München

80335

GSK Investigational Site, München

80336

GSK Investigational Site, München

80801

GSK Investigational Site, München

81675

GSK Investigational Site, München

99427

GSK Investigational Site, Weimar

09111

GSK Investigational Site, Chemnitz

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

MUC Research GmbH
All Listed Sponsors
collaborator

MUC Research GmbH

OTHER

lead

ViiV Healthcare

INDUSTRY

NCT03518060 - Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1 | Biotech Hunter | Biotech Hunter